Kimm B Galbraith

US Patent:

20040254174, Dec 16, 2004

Filed:

May 7, 2004

Appl. No.:

10/841075

Inventors:

Scott Perrin - Boothwyn PA, US
Kimm Galbraith - Spring City PA, US
Naidong Ye - Malvern PA, US

Assignee:

Vela Pharmaceuticals, Inc. - Ewing NJ

International Classification:

A61K031/5513
C07D243/00

US Classification:

514/221000, 540/567000

Abstract:

(R)-tofisopam, substantially free of the (S)-enantiomer of tofisopam, is obtained by separating the enantiomers of tofisopam by chromatography employing a chiral separation medium comprising (i) (2S)-2-{(1S)[(3,5-dinitrophenyl)carbonylamino]phenylmethyl}-3,3-dimethylbutanoate, covalently bound to silica through an alkylene ester linkage or (ii) an amylose derivative of formula I: wherein each Rand n are defined herein; the amylose derivative being coated on a porous inorganic carrier or a porous organic carrier.

US Patent:

20060128955, Jun 15, 2006

Filed:

Dec 15, 2005

Appl. No.:

11/305490

Inventors:

Scott Perrin - Boothwyn PA, US
Naidong Ye - Malvern PA, US
Kimm Galbraith - Spring City PA, US
Wilhelm Hauck - Wallingford PA, US

Assignee:

Vela Pharmaceuticals, Inc. - Ewing NJ

International Classification:

C07D 243/10

US Classification:

540567000

Abstract:

The present invention is directed to a process for the isolation of (R)-tofisopam with high enantiomeric purity and high overall yields from a mixture of tofisopam enantiomers by means of a non-steady state continuous chromatographic process.

US Patent:

20060264421, Nov 23, 2006

Filed:

May 23, 2005

Appl. No.:

11/135100

Inventors:

Yong Wei - Branchburg NJ, US
Naidong Ye - Malvern PA, US
Kimm Galbraith - Spring City PA, US
Jianfeng Shi - Baltimore MD, US
Wuyi Wang - Silver Spring MD, US
Yungen Xu - Baltimore MD, US
Mallikarjun Ravi - Baltimore MD, US

Assignee:

Vela Pharmaceuticals, Inc. - Ewing NJ

International Classification:

A61K 31/5513
C07D 487/02

US Classification:

514221000, 540567000

Abstract:

Methods for the racemization of an enantiomer of a 2,3-benzodiazepine molecule into the corresponding racemic mixture under either basic or acidic conditions are described. Furthermore, the invention relates to the conversion of an enantiomer of tofisopam or its metabolites to the corresponding opposite enantiomer.